The Defender reports “Arcturus Therapeutics announced earlier this week that the U.S. Food and Drug Administration (FDA) issued a “Study Can Proceed” notification for its investigational ARCT-2304 vaccine candidate.” Jessica Rose PhD says there are “major red flags.”
The Defender also reported that “In clinical trials for the self-amplifying COVID-19 vaccine offered in Japan, “five deaths occurred among the injected in study phase 3b. Injected participants experienced a 90% adverse event rate (74.5% systemic, 15.2% required medical attention) after the first dose in study phases 1, 2, and 3a combined…”
Dr. Clare Craig, BM BCh FRCPath, is a diagnostic pathologist, author, and co-chair of HART (Health Advisory and Recovery Team). She studied medicine at Cambridge and completed clinical training at Oxford. After 15 years in the NHS, she became pathology lead for the cancer arm of the 100,000 Genomes Project at Genomics England. She is the author of “Expired: Covid the Untold Story” and advocates for public education on COVID. Find more at https://hart.org and https://x.com/ClareCraigPath
Dr. Jessica Rose is a Canadian researcher with a Bachelor’s in Applied Mathematics and a Master’s in Immunology from Memorial University of Newfoundland. She holds a PhD in Computational Biology from Bar Ilan University and completed postdoctoral research in Molecular Biology at the Hebrew University of Jerusalem and Biochemistry at the Technion Institute of Technology. Her recent work focuses on descriptive analysis of Vaccine Adverse Event Reporting System (VAERS) data. Find her at https://jessicasuniverse.com and https://jessicar.substack.com
